By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CBLPath has received approval in New York to offer in-house Roche's cobas 4800 BRAF V600 Mutation Test for metastatic melanoma. The approval from the New York State Department of Health makes CBLPath one of a few laboratories in the US to offer the test, the Rye Brook, NY-based lab said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.